Gregory A. Gould

Insider · CFO · ACON

Gregory A. Gould files insider transactions with the SEC as a cfo of Aclarion (ACON). We hold 1 disclosed purchase or sale filed since 5 October 2006, 1 of them in the last 90 days.

Files forACON
Disclosed buys and sells1 in all, 1 in the last 90 days
Last disclosure18 August 2026

Positions held

7 posts we hold — a term names its own dates; a run of filings only says when they filed

Filed 2 September 2025 — 14 August 2026CFO · Aclarion (ACON)3 Form 4 lines · source: SEC Form 4
Filed 17 June 2022 — 17 June 2022Chief Financial Officer · Charlotte's Web Holdings (CWBHF)1 Form 4 line · source: SEC Form 4
Filed 1 July 2019 — 2 July 2021Chief Financial Officer · NewAge (NBEV)10 Form 4 lines · source: SEC Form 4
Filed 20 March 2006 — 18 June 2019Director · CytoDyn (CYDY)51 Form 4 lines · source: SEC Form 4
Filed 11 November 2015 — 16 March 2017Chief Financial Officer · Aytu Bioscience (AYTU)14 Form 4 lines · source: SEC Form 4
Filed 30 July 2015 — 15 July 2016Chief Financial Officer · Ampio Pharmaceuticals (AMPE)2 Form 4 lines · source: SEC Form 4
Filed 3 October 2006 — 20 April 2012Interim CEO, CFO, Treas & Sec. · Seracare Life Sciences (SRLS)28 Form 4 lines · source: SEC Form 4

Everything they disclosed

109 entries, newest first — one per disclosure report, one per Form 4 line

▲ bought on the open market 10,000 shares of AclarionSEC Form 418 August 2026Common Stock · traded 14 August 2026 · filed 18 August 2026
was granted 50,000 shares of AclarionSEC Form 412 June 2026Common Stock · traded 11 June 2026 · filed 12 June 2026
was granted 17,000 shares of Aclarion (a derivative holding)SEC Form 43 September 2025Stock Option (right to buy) · traded 2 September 2025 · filed 3 September 2025
was granted 1,200,000 shares of Charlotte's Web Holdings (a derivative holding)SEC Form 421 June 2022Stock Option (right to buy) · traded 17 June 2022 · filed 21 June 2022
had shares withheld for tax on 73,110 shares of NewAgeSEC Form 47 July 2021Common Stock · traded 2 July 2021 · filed 7 July 2021
was granted 125,000 shares of NewAge (a derivative holding)SEC Form 412 March 2021Stock Option (Right to Buy) · traded 10 March 2021 · filed 12 March 2021
had shares withheld for tax on 26,507 shares of NewAgeSEC Form 45 January 2021Common Stock · traded 5 January 2021 · filed 5 January 2021
had shares withheld for tax on 9,564 shares of NewAgeSEC Form 411 December 2020Common Stock · traded 10 December 2020 · filed 11 December 2020
had shares withheld for tax on 9,564 shares of NewAgeSEC Form 426 October 2020Common Stock · traded 22 October 2020 · filed 26 October 2020
was granted 100,000 shares of New Age Beverages (a derivative holding)SEC Form 412 December 2019Stock Option (Right to Buy) · traded 10 December 2019 · filed 12 December 2019
was granted 100,000 shares of New Age BeveragesSEC Form 412 December 2019Common Stock · traded 10 December 2019 · filed 12 December 2019
was granted 100,000 shares of New Age Beverages (a derivative holding)SEC Form 43 July 2019Stock Option (right to buy) · traded 1 July 2019 · filed 3 July 2019
was granted 100,000 shares of New Age BeveragesSEC Form 43 July 2019Common Stock · traded 1 July 2019 · filed 3 July 2019
was granted 250,000 shares of New Age BeveragesSEC Form 43 July 2019Common Stock · traded 1 July 2019 · filed 3 July 2019
was granted 100,000 shares of CytoDyn (a derivative holding)SEC Form 419 June 2019Stock Options (right to buy) · traded 18 June 2019 · filed 19 June 2019
was granted 19,176 shares of CytoDynSEC Form 419 November 2018Common Stock · traded 16 November 2018 · filed 19 November 2018
was granted 50,000 shares of CytoDyn (a derivative holding)SEC Form 419 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 19 November 2018
was granted 50,000 shares of CytoDyn (a derivative holding)SEC Form 419 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 19 November 2018
was granted 25,000 shares of CytoDyn (a derivative holding)SEC Form 419 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 19 November 2018
was granted 50,000 shares of CytoDyn (a derivative holding)SEC Form 419 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 19 November 2018
was granted 50,000 shares of CytoDyn (a derivative holding)SEC Form 419 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 19 November 2018
was granted 100,000 shares of CytoDyn (a derivative holding)SEC Form 419 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 19 November 2018
was granted 75,000 shares of CytoDyn (a derivative holding)SEC Form 419 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 19 November 2018
was granted 160,662 shares of CytoDyn (a derivative holding)SEC Form 419 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 19 November 2018
was granted 50,000 shares of CytoDyn (a derivative holding)SEC Form 419 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 19 November 2018
was granted 100,000 shares of CytoDyn (a derivative holding)SEC Form 419 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 19 November 2018
returned to the issuer 19,176 shares of CytoDynSEC Form 416 November 2018Common Stock · traded 16 November 2018 · filed 16 November 2018
returned to the issuer 50,000 shares of CytoDyn (a derivative holding)SEC Form 416 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 16 November 2018
returned to the issuer 50,000 shares of CytoDyn (a derivative holding)SEC Form 416 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 16 November 2018
returned to the issuer 25,000 shares of CytoDyn (a derivative holding)SEC Form 416 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 16 November 2018
returned to the issuer 50,000 shares of CytoDyn (a derivative holding)SEC Form 416 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 16 November 2018
returned to the issuer 50,000 shares of CytoDyn (a derivative holding)SEC Form 416 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 16 November 2018
returned to the issuer 100,000 shares of CytoDyn (a derivative holding)SEC Form 416 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 16 November 2018
returned to the issuer 75,000 shares of CytoDyn (a derivative holding)SEC Form 416 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 16 November 2018
returned to the issuer 160,662 shares of CytoDyn (a derivative holding)SEC Form 416 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 16 November 2018
returned to the issuer 50,000 shares of CytoDyn (a derivative holding)SEC Form 416 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 16 November 2018
returned to the issuer 100,000 shares of CytoDyn (a derivative holding)SEC Form 416 November 2018Stock Options (right to buy) · traded 16 November 2018 · filed 16 November 2018
was granted 100,000 shares of CytoDyn (a derivative holding)SEC Form 412 June 2018Stock Options (right to buy) · traded 8 June 2018 · filed 12 June 2018
returned to the issuer 50,000 shares of CytoDyn (a derivative holding)SEC Form 416 February 2018Stock Options (right to buy) · traded 15 February 2018 · filed 16 February 2018
was granted 50,000 shares of CytoDyn (a derivative holding)SEC Form 416 February 2018Stock Options (right to buy) · traded 15 February 2018 · filed 16 February 2018
was granted 160,662 shares of CytoDyn (a derivative holding)SEC Form 49 February 2018Stock Options (right to buy) · traded 7 February 2018 · filed 9 February 2018
was granted 75,000 shares of CytoDyn (a derivative holding)SEC Form 45 June 2017Stock Options (right to buy) · traded 1 June 2017 · filed 5 June 2017
returned to the issuer 20,834 shares of Aytu Bioscience (a derivative holding)SEC Form 417 March 2017Employee Stock Option Grant · traded 16 March 2017 · filed 17 March 2017
returned to the issuer 25,000 shares of Aytu Bioscience (a derivative holding)SEC Form 417 March 2017Employee Stock Option Grant · traded 16 March 2017 · filed 17 March 2017
was granted 20,834 shares of Aytu Bioscience (a derivative holding)SEC Form 417 March 2017Employee Stock Option Grant · traded 16 March 2017 · filed 17 March 2017
was granted 25,000 shares of Aytu Bioscience (a derivative holding)SEC Form 417 March 2017Employee Stock Option Grant · traded 16 March 2017 · filed 17 March 2017
exercised options over 66,666 shares of Aytu BioscienceSEC Form 41 March 2017Common Stock · traded 27 February 2017 · filed 1 March 2017
exercised options over 66,666 shares of Aytu Bioscience (a derivative holding)SEC Form 41 March 2017Warrant to Purchase Common Stock · traded 27 February 2017 · filed 1 March 2017
was granted 100,000 shares of CytoDyn (a derivative holding)SEC Form 421 November 2016Stock Option (right to buy) · traded 17 November 2016 · filed 21 November 2016
▲ bought on the open market 66,666 shares of Aytu BioscienceSEC Form 44 November 2016Common Stock · traded 2 November 2016 · filed 4 November 2016
▲ bought on the open market 66,666 shares of Aytu Bioscience (a derivative holding)SEC Form 44 November 2016Warrant to Purchase Common Stock · traded 2 November 2016 · filed 4 November 2016
was granted 41,899 shares of Aytu BioscienceSEC Form 44 August 2016Common Stock · traded 2 August 2016 · filed 4 August 2016
was granted 150,000 shares of Ampio Pharmaceuticals (a derivative holding)SEC Form 419 July 2016Stock Option (Right to Buy) · traded 15 July 2016 · filed 19 July 2016
was granted 165,000 shares of Aytu BioscienceSEC Form 411 July 2016Common Stock · traded 7 July 2016 · filed 11 July 2016
returned to the issuer 20,834 shares of Aytu Bioscience (a derivative holding)SEC Form 411 July 2016Employee Stock Option Grant · traded 7 July 2016 · filed 11 July 2016
was granted 20,834 shares of Aytu Bioscience (a derivative holding)SEC Form 411 July 2016Employee Stock Option Grant · traded 7 July 2016 · filed 11 July 2016
was granted 25,000 shares of Aytu Bioscience (a derivative holding)SEC Form 411 July 2016Employee Stock Option Grant · traded 7 July 2016 · filed 11 July 2016
was granted 50,000 shares of CytoDyn (a derivative holding)SEC Form 43 June 2016Stock Options (right to buy) · traded 1 June 2016 · filed 3 June 2016
returned to the issuer 50,000 shares of Cytodyn (a derivative holding)SEC Form 423 December 2015Stock Options (right to buy) · traded 21 December 2015 · filed 23 December 2015
was granted 50,000 shares of Cytodyn (a derivative holding)SEC Form 423 December 2015Stock Options (right to buy) · traded 21 December 2015 · filed 23 December 2015
returned to the issuer 25,000 shares of Cytodyn (a derivative holding)SEC Form 423 December 2015Stock Options (right to buy) · traded 21 December 2015 · filed 23 December 2015
was granted 25,000 shares of Cytodyn (a derivative holding)SEC Form 423 December 2015Stock Options (right to buy) · traded 21 December 2015 · filed 23 December 2015
returned to the issuer 50,000 shares of Cytodyn (a derivative holding)SEC Form 423 December 2015Stock Options (right to buy) · traded 21 December 2015 · filed 23 December 2015
was granted 50,000 shares of Cytodyn (a derivative holding)SEC Form 423 December 2015Stock Options (right to buy) · traded 21 December 2015 · filed 23 December 2015
was granted 250,000 shares of Aytu Bioscience (a derivative holding)SEC Form 413 November 2015Employee Stock Option Grant · traded 11 November 2015 · filed 13 November 2015
was granted 100,000 shares of Ampio Pharmaceuticals (a derivative holding)SEC Form 43 August 2015Stock Option (right to buy) · traded 30 July 2015 · filed 3 August 2015
was granted 50,000 shares of Cytodyn (a derivative holding)SEC Form 42 June 2015Stock Options (right to buy) · traded 1 June 2015 · filed 2 June 2015
was granted 50,000 shares of Cytodyn (a derivative holding)SEC Form 42 June 2014Stock Options (right to buy) · traded 1 June 2014 · filed 2 June 2014
was granted 50,000 shares of Cytodyn (a derivative holding)SEC Form 43 June 2013Stock Options (right to buy) · traded 1 June 2013 · filed 3 June 2013
was granted 3,125 shares of CytodynSEC Form 43 June 2013Common Stock · traded 31 May 2013 · filed 3 June 2013
was granted 2,500 shares of CytodynSEC Form 44 March 2013Common Stock · traded 28 February 2013 · filed 4 March 2013
was granted 1,562 shares of CytodynSEC Form 44 December 2012Common Stock · traded 30 November 2012 · filed 4 December 2012
was granted 3,246 shares of CytodynSEC Form 45 September 2012Common Stock · traded 31 August 2012 · filed 5 September 2012
was granted 25,000 shares of Cytodyn (a derivative holding)SEC Form 44 June 2012Options (right to purchase) · traded 1 June 2012 · filed 4 June 2012
was granted 3,743 shares of CytodynSEC Form 423 May 2012Common Stock · traded 21 May 2012 · filed 23 May 2012
returned to the issuer 75,000 shares of Seracare Life Sciences (a derivative holding)SEC Form 420 April 2012Stock Option (Right to Buy) · traded 20 April 2012 · filed 20 April 2012
returned to the issuer 46,666 shares of Seracare Life Sciences (a derivative holding)SEC Form 420 April 2012Stock Option (Right to Buy) · traded 20 April 2012 · filed 20 April 2012
returned to the issuer 23,334 shares of Seracare Life Sciences (a derivative holding)SEC Form 420 April 2012Stock Option (Right to Buy) · traded 20 April 2012 · filed 20 April 2012
returned to the issuer 237,844 shares of Seracare Life SciencesSEC Form 420 April 2012Common Stock · traded 20 April 2012 · filed 20 April 2012
had shares withheld for tax on 1,119 shares of Seracare Life SciencesSEC Form 49 March 2012Common Stock · traded 8 March 2012 · filed 9 March 2012
was granted 1,492 shares of Seracare Life SciencesSEC Form 42 February 2012Common Stock · traded 1 February 2012 · filed 2 February 2012
was granted 1,613 shares of Seracare Life SciencesSEC Form 44 January 2012Common Stock · traded 3 January 2012 · filed 4 January 2012
had shares withheld for tax on 3,964 shares of Seracare Life SciencesSEC Form 49 December 2011Common Stock · traded 8 December 2011 · filed 9 December 2011
was granted 1,710 shares of Seracare Life SciencesSEC Form 42 December 2011Common Stock · traded 1 December 2011 · filed 2 December 2011
was granted 50,000 shares of Seracare Life SciencesSEC Form 417 November 2011Common Stock · traded 16 November 2011 · filed 17 November 2011
was granted 5,157 shares of Seracare Life SciencesSEC Form 48 November 2011Common Stock · traded 7 November 2011 · filed 8 November 2011
was granted 25,000 shares of Cytodyn (a derivative holding)SEC Form 431 October 2011Options (right to acquire) · traded 20 March 2006 · filed 31 October 2011
was granted 25,000 shares of Cytodyn (a derivative holding)SEC Form 431 October 2011Options (right to acquire) · traded 27 September 2006 · filed 31 October 2011
was granted 25,000 shares of Cytodyn (a derivative holding)SEC Form 431 October 2011Options (right to acquire) · traded 31 March 2007 · filed 31 October 2011
was granted 25,000 shares of Cytodyn (a derivative holding)SEC Form 431 October 2011Options (right to acquire) · traded 11 August 2008 · filed 31 October 2011
was granted 125,000 shares of Cytodyn (a derivative holding)SEC Form 431 October 2011Options (right to acquire) · traded 13 January 2010 · filed 31 October 2011
was granted 50,000 shares of Cytodyn (a derivative holding)SEC Form 411 August 2011Options (right to acquire) · traded 9 August 2011 · filed 11 August 2011
was granted 80,000 shares of Seracare Life SciencesSEC Form 42 August 2011Common Stock · traded 1 August 2011 · filed 2 August 2011
was granted 50,000 shares of Seracare Life SciencesSEC Form 410 December 2010Common Stock · traded 8 December 2010 · filed 10 December 2010
was granted 2,589 shares of Seracare Life SciencesSEC Form 42 April 2010Common Stock · traded 1 April 2010 · filed 2 April 2010
was granted 2,700 shares of Seracare Life SciencesSEC Form 45 January 2010Common Stock · traded 4 January 2010 · filed 5 January 2010
was granted 23,333 shares of Seracare Life Sciences (a derivative holding)SEC Form 420 November 2009Non-Qualified Stock Option (Right to Buy) · traded 18 November 2009 · filed 20 November 2009
was granted 23,333 shares of Seracare Life Sciences (a derivative holding)SEC Form 420 November 2009Non-Qualified Stock Option (Right to Buy) · traded 18 November 2009 · filed 20 November 2009
was granted 23,334 shares of Seracare Life Sciences (a derivative holding)SEC Form 420 November 2009Non-Qualified Stock Option (Right to Buy) · traded 18 November 2009 · filed 20 November 2009
was granted 35,141 shares of Seracare Life SciencesSEC Form 420 November 2009Common Stock · traded 18 November 2009 · filed 20 November 2009
was granted 4,017 shares of Seracare Life SciencesSEC Form 42 October 2009Common Stock · traded 1 October 2009 · filed 2 October 2009
was granted 8,508 shares of Seracare Life SciencesSEC Form 42 July 2009Common Stock · traded 1 July 2009 · filed 2 July 2009
was granted 25,000 shares of Seracare Life Sciences (a derivative holding)SEC Form 425 November 2008Non-Qualified Stock Option (Right to Buy) · traded 21 November 2008 · filed 25 November 2008
was granted 25,000 shares of Seracare Life Sciences (a derivative holding)SEC Form 425 November 2008Non-Qualified Stock Option (Right to Buy) · traded 21 November 2008 · filed 25 November 2008
was granted 25,000 shares of Seracare Life Sciences (a derivative holding)SEC Form 425 November 2008Non-Qualified Stock Option (Right to Buy) · traded 21 November 2008 · filed 25 November 2008
was granted 16,666 shares of Seracare Life Sciences (a derivative holding)SEC Form 420 November 2007Nonqualified Stock Option (Right to Buy) · traded 14 November 2007 · filed 20 November 2007
was granted 16,667 shares of Seracare Life Sciences (a derivative holding)SEC Form 420 November 2007Nonqualified Stock Option (Right to Buy) · traded 14 November 2007 · filed 20 November 2007
was granted 16,667 shares of Seracare Life Sciences (a derivative holding)SEC Form 420 November 2007Nonqualified Stock Option (Right to Buy) · traded 14 November 2007 · filed 20 November 2007
was granted 250,000 shares of Seracare Life Sciences (a derivative holding)SEC Form 45 October 2006Employee Stock Option (Right to Buy) · traded 3 October 2006 · filed 5 October 2006

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.